Keith W Pratz, MD
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director, Leukemia Programs, University of Pennsylvania/Abramson Cancer Center
Section Chief Leukemia, University of Pennyslvania
Department: Medicine
Contact information
3400 Civic Center Blvd.
South Pavilion Room 12-155
Philadelphia, PA 19104
South Pavilion Room 12-155
Philadelphia, PA 19104
Education:
BS (Molecular Biology)
University of Maryland at College Park, 1998.
MD (Medicine )
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 2002.
Permanent linkBS (Molecular Biology)
University of Maryland at College Park, 1998.
MD (Medicine )
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 2002.
Description of Clinical Expertise
Hematologic Malignancies, Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, MDS, AML, ALL, CML, bone Marrow TransplantDescription of Research Expertise
Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, MDS, AML, ALL, CMLSelected Publications
Michaela Liedtke, Zhuoxin Sun, Mark R. Litzow, Ryan J Mattison, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevskis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W. Pratz, Shira N. Dinner, Noelle Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Cheryl L. Willman, Daniel J. DeAngelo, Shejal B. Patel, Michelle A Elliott, Anjali S. Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Bhave, Elad Sharon, Richard Little, Harry P. Erba, Richard M. Stone, Selina Luger, Charles G. Mullighan, Martin S. Tallman, Matthew J. Wieduwilt: Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial. Blood Dec 2025.Pratz KW, Erba HP : Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents. Am J Hematol Mar 2025.
Pullarkat V, Pratz KW, Döhner H, Recher C, Thirman MJ, DiNardo CD, Fenaux P, Schuh AC, Wei AH, Pigneux A, Jang JH, Juliusson G, Miyazaki Y, Selleslag D, Arellano ML, Liu C, Ridgeway JA, Potluri J, Schuler J, Konopleva M: Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood Cancer J Mar 2025.
Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv 9: 533-544, Feb 2025.
Alison Carulli, Brendan L. Mangan, Rachel Hartman, Mrs. Lindsey MacDonald, Mr. Christopher J. Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Mary Ellen Martin, Nasheed M. Hossain, Alison W. Loren, Selina M. Luger, Shannon R. McCurdy, David L Porter, Keith W. Pratz, Jacqueline Smith, Pashna Munshi: Early Mixed Chimerism and Relapse Rates for Acute Myeloid Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy Feb 2025.
Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J. : Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 2025.
Pratz KW, Erba HP.: Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents. Am J Hematol 2025.
Amir T. Fathi, Ghayas C. Issa, Eunice S. Wang, Harry Erba, Jessica Kaplan Altman, Suresh Kumar Balasubramanian, Gail J. Roboz, Gary J. Schiller, Christine M. McMahon, Neil D. Palmisiano, Mark B Juckett, Yazan F. Madanat, Marcello Rotta, Keith W. Pratz, George Yaghmour, Kalyan Nadiminti, Helen Wei, Marcie Riches, Daniel Corum, Mollie Leoni, Stephen Dale, Amer M. Zeidan: Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. Blood Dec 2024.
Nikolai A. Podoltsev, Zhuoxin Sun, Mark R. Litzow, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevskis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Matthew J. Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W. Pratz, Shira N. Dinner, Noelle Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Cheryl L. Willman, Daniel J. DeAngelo, Shejal B. Patel, Michelle A Elliott, Anjali S. Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy, Elad Sharon, Richard Little, Harry Erba, Richard M. Stone, Charles G. Mullighan, Martin S. Tallman, Selina Luger, Ryan J Mattison: Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial. Blood Dec 2024.
Pratz KW: Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1. Br J Haematol Dec 2024.